Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203398 | 0.83 | PDCD1 (0.36) | LMNANPC1RAB9ATP53TSHR | |
| SCHEMBL21403201 | 0.83 | PDCD1 (0.36) | LMNANPC1RAB9ATP53TSHR | |
| SCHEMBL23733434 | 0.83 | NPC1 (0.33) | LMNANPC1RAB9ATP53TSHR | |
| SCHEMBL20037707 | 0.83 | NPSR1 (0.35) | LMNANPC1RAB9ATP53TSHR | |
| SCHEMBL20203508 | 0.82 | CYP2C9 (0.36) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL26180774 | 0.82 | PKM (0.36) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL20203512 | 0.81 | AKT1 (0.34) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL21403227 | 0.81 | AKT1 (0.34) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL23733435 | 0.79 | MEN1 (0.35) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL20207266 | 0.68 | SMN1; SMN2 (0.37) | LMNANPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | LMNA 3711/4885CYP1A2 2489/4885CYP2D6 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.